<DOC>
	<DOCNO>NCT00319228</DOCNO>
	<brief_summary>To assess safety , pharmacokinetics efficacy plasma-derived AT-III concentrate treatment subject congenital AT-III deficiency .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Efficacy AT-III Concentrate .</brief_title>
	<detailed_description>This study prospective , unblinded , non-randomized , open-label , multi-center Phase II/III study 2 segment , i.e . PK evaluation ( Segment I ) , assessment prophylaxis surgical intervention pregnancy/delivery , ( Segment II ) . During PK segment , subject would remain current anticoagulation therapy except subject heparin therapy wash-out period least 5 half life would require . In total , 15 subject congenital ATIII Deficiency enrol PK assessment ( Segment I ) . For Segment II , fifteen episode treat . Recruitment individual subject high risk venous thrombosis Segment II study necessary rarity Antithrombin deficiency population .</detailed_description>
	<mesh_term>Antithrombin III Deficiency</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<criteria>Congenital ATIII deficiency document determination plasma level ATIII therapy . Specifically , baseline level ATIII activity equal le 60 % . Age &gt; 12 year body weight less 30 kg . Have participate another investigational study least 30 day For Segment II , enrollment require pregnancy/delivery surgical procedure ( major surgery although data minor surgery also collect ) . Documented personal history major thromboembolic thrombotic event . Male female HIV , HBV , HCV , HAV PARVO B19 status know prior entry . The subject willing comply aspect protocol , include blood sampling , duration study . The subject sign informed consent form ( least 18 year old ) , subject 's parent legal guardian sign informed consent form . Subjects age 18 year also ask sign assent form . All consent assent form must approve advance Institutional Review Board investigator 's institution . Patients heparinassociated thrombocytopenia require anticoagulation nonheparin contain drug eligible safely transition washout period Segment I PK study . If pregnant , woman must Parvo B19 IgG antibody positive . Acquired deficiency ATIII Receiving concomitant treatment thrombophilic disorder ATIII deficiency Inability unwillingness comply protocol requirement History anaphylactic reaction ( ) blood blood component Allergies excipients . Liver function test &gt; /= 2.5 X ULN Serum creatinine &gt; 1.2 X ULN Urine &gt; /= 2+ protein urine dipstick test . The subject know abused alcohol illicit drug within past 12 month . The subject unlikely adhere protocol requirement study likely uncooperative unable provide storage serum sample screen visit . Patients heparintreatment , clinical reason , safely discontinue heparin therapy PK segment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AT-III deficiency</keyword>
	<keyword>AT-III concentrate</keyword>
	<keyword>Bleeding disorder</keyword>
	<keyword>Blood disorder</keyword>
</DOC>